Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Source: SeekingAlpha
2026-03-10 00:47:58 ET
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile March 9, 2026 6:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Telix Pharmaceuticals Ltd
NASDAQ: TLPPF
TLPPF Trading
2.92% G/L:
$6.70 Last:
5,100 Volume:
$6.60 Open:
